These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38436714)

  • 1. Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.
    Yücel KB; Aydos U; Sütcüoglu O; Kılıç ACK; Özdemir N; Özet A; Yazıcı O
    Cancer Chemother Pharmacol; 2024 May; 93(5):497-507. PubMed ID: 38436714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
    Franzoi MA; Vandeputte C; Eiger D; Caparica R; Brandão M; De Angelis C; Hendlisz A; Awada A; Piccart M; de Azambuja E
    Breast Cancer Res Treat; 2020 May; 181(1):199-209. PubMed ID: 32246377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do body composition parameters correlate with response to targeted therapy in ER+/HER2- metastatic breast cancer patients? Role of sarcopenia and obesity.
    Kripa E; Rizzo V; Galati F; Moffa G; Cicciarelli F; Catalano C; Pediconi F
    Front Oncol; 2022; 12():987012. PubMed ID: 36212446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
    Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
    Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body composition measures as a determinant of Alpelisib related toxicity.
    Shachar E; Raphael A; Katz U; Kessner R; Shachar SS
    Breast Cancer Res Treat; 2024 Jul; 206(2):369-376. PubMed ID: 38584192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low subcutaneous adipose tissue and myosteatosis are prognostic factors after allogeneic hematopoietic stem cell transplantation.
    Barajas Ordonez F; Zeller Y; Wolleschak D; Hinnerichs M; Rodríguez-Feria P; Mougiakakos D; Aghayev A; Kardas H; Mikusko M; Borggrefe J; Surov A
    Clin Nutr ESPEN; 2024 Jun; 61():274-280. PubMed ID: 38777443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
    Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
    PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of body composition measures in breast cancer patients treated with chemotherapy.
    Kang H; Kim I; Park H; Ahn W; Kim SK; Lee S
    Sci Rep; 2024 Oct; 14(1):23309. PubMed ID: 39375403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer.
    Barret M; Antoun S; Dalban C; Malka D; Mansourbakht T; Zaanan A; Latko E; Taieb J
    Nutr Cancer; 2014; 66(4):583-9. PubMed ID: 24707897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of body composition on outcome in patients with early breast cancer.
    Deluche E; Leobon S; Desport JC; Venat-Bouvet L; Usseglio J; Tubiana-Mathieu N
    Support Care Cancer; 2018 Mar; 26(3):861-868. PubMed ID: 28948392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of anthropometric measures extracted from whole-body CT using deep learning in patients with non-small-cell lung cancer.
    Blanc-Durand P; Campedel L; Mule S; Jegou S; Luciani A; Pigneur F; Itti E
    Eur Radiol; 2020 Jun; 30(6):3528-3537. PubMed ID: 32055950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Skeletal Muscle Loss and Visceral Obesity Measured Using Serial CT on the Prognosis of Operable Breast Cancers in Asian Patients.
    Kwon MR; Ko ES; Park MS; Jeong WK; Hwang NY; Kim JH; Lee JE; Kim SW; Yu JH; Han BK; Ko EY; Choi JS; Park KW
    Korean J Radiol; 2022 Feb; 23(2):159-171. PubMed ID: 35029082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
    Liu M; Jin Q; Wang H; Li Y
    Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
    Yıldırım HÇ; Mutlu E; Chalabiyev E; Özen M; Keskinkılıç M; Ön S; Çelebi A; Dursun B; Acar Ö; Kahraman S; Aykan MB; Kaman Ö; Doğan A; Erdoğan AP; Melisa Celayir Ö; Günenç D; Güven DC; Vedat Bayoğlu İ; Yavuzşen T; Hacıbekiroğlu İ; İnanç M; Kılıçkap S; Yalçın Ş; Aksoy S
    Breast; 2022 Dec; 66():85-88. PubMed ID: 36208540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Piezzo M; Chiodini P; Riemma M; Cocco S; Caputo R; Cianniello D; Di Gioia G; Di Lauro V; Rella FD; Fusco G; Iodice G; Nuzzo F; Pacilio C; Pensabene M; De Laurentiis M
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
    Spring L; Bardia A; Modi S
    Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.